RESUMEN
Interferons are polypeptides that naturally occur in the human body as a part of the innate immune response. By harnessing these immunomodulatory functions, synthetic interferons have shown efficacy in combating various diseases including cutaneous T-cell lymphoma. This article closely examines the qualities of interferon alfa and interferon gamma and the evidence behind their use in the 2 most common types of cutaneous T-cell lymphomas, namely, mycosis fungoides and Sézary syndrome.
Asunto(s)
Interferón-alfa/uso terapéutico , Interferón gamma/uso terapéutico , Micosis Fungoide/tratamiento farmacológico , Neoplasias Cutáneas/tratamiento farmacológico , Antineoplásicos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Terapia Combinada/métodos , Humanos , Interferón-alfa/efectos adversos , Interferón-alfa/farmacología , Interferón beta/uso terapéutico , Interferón gamma/efectos adversos , Interferón gamma/farmacología , Micosis Fungoide/terapia , Terapia PUVA/métodos , Retinoides/uso terapéutico , Neoplasias Cutáneas/terapiaAsunto(s)
Linfoma Cutáneo de Células T/tratamiento farmacológico , Linfoma Cutáneo de Células T/patología , Terapia PUVA/métodos , Anticarcinógenos/uso terapéutico , Terapia Combinada , Femenino , Estudios de Seguimiento , Humanos , Inmunosupresores/uso terapéutico , Masculino , Invasividad Neoplásica/patología , Estadificación de Neoplasias , Medición de Riesgo , Muestreo , Resultado del TratamientoRESUMEN
Sézary syndrome (SS) has a poor prognosis and few guidelines for optimizing therapy. The US Cutaneous Lymphoma Consortium, to improve clinical care of patients with SS and encourage controlled clinical trials of promising treatments, undertook a review of the published literature on therapeutic options for SS. An overview of the immunopathogenesis and standardized review of potential current treatment options for SS including metabolism, mechanism of action, overall efficacy in mycosis fungoides and SS, and common or concerning adverse effects is first discussed. The specific efficacy of each treatment for SS, both as monotherapy and combination therapy, is then reported using standardized criteria for both SS and response to therapy with the type of study defined by a modification of the US Preventive Services guidelines for evidence-based medicine. Finally, guidelines for the treatment of SS and suggestions for adjuvant treatment are noted.
Asunto(s)
Síndrome de Sézary/patología , Síndrome de Sézary/terapia , Neoplasias Cutáneas/patología , Neoplasias Cutáneas/terapia , Alquilantes/uso terapéutico , Anticuerpos Monoclonales/uso terapéutico , Antineoplásicos/uso terapéutico , Ensayos Clínicos como Asunto , Terapia Combinada , Quimioterapia Combinada , Medicina Basada en la Evidencia , Inhibidores de Histona Desacetilasas/uso terapéutico , Humanos , Factores Inmunológicos/uso terapéutico , Metotrexato/uso terapéutico , Micosis Fungoide/patología , Micosis Fungoide/terapia , Calidad de Vida , Retinoides/uso terapéutico , Síndrome de Sézary/inmunología , Neoplasias Cutáneas/inmunologíaRESUMEN
BACKGROUND: Hypericin is a known photodynamic agent that has been demonstrated to induce apoptosis in normal and malignant B and T lymphocytes, and has potential to treat benign and malignant disorders of the skin, including psoriasis and cutaneous T-cell lymphoma. OBJECTIVE: We wished to test whether topical hypericin was an effective, safe, and well-tolerated therapy for patch or plaque phase mycosis fungoides and for plaque psoriasis. METHODS: We conducted a phase II placebo-controlled clinical study in patients who had either patch or plaque phase mycosis fungoides or plaque type psoriasis vulgaris. Representative lesions were treated twice weekly for 6 weeks with topically applied hypericin or placebo followed 24 hours later by exposure to visible light at 8 to 20 J/cm(2). RESULTS: After 6 weeks of twice-weekly therapy, several concentrations of hypericin resulted in the significant improvement of treated skin lesions among the majority of patients with cutaneous T-cell lymphoma and psoriasis whereas the placebo vehicle was ineffective. LIMITATIONS: The clinical trial involved a small number of patients. CONCLUSIONS: Overall, the data from this study support the conclusion that topical hypericin/visible light photodynamic therapy is an effective and well-tolerated alternative to standard psoralen plus ultraviolet A treatment of these disorders.
Asunto(s)
Luz , Linfoma Cutáneo de Células T/tratamiento farmacológico , Perileno/análogos & derivados , Fotoquimioterapia/métodos , Psoriasis/tratamiento farmacológico , Neoplasias Cutáneas/tratamiento farmacológico , Administración Tópica , Adolescente , Adulto , Anciano , Antracenos , Antineoplásicos/administración & dosificación , Antineoplásicos/efectos adversos , Femenino , Humanos , Linfoma Cutáneo de Células T/complicaciones , Masculino , Persona de Mediana Edad , Perileno/administración & dosificación , Perileno/efectos adversos , Fotoquimioterapia/efectos adversos , Fototerapia/efectos adversos , Placebos , Psoriasis/complicaciones , Neoplasias Cutáneas/complicaciones , Resultado del Tratamiento , Adulto JovenRESUMEN
PURPOSE OF REVIEW: Cutaneous T-cell lymphomas (CTCLs) are a heterogenous group of non-Hodgkin's lymphomas characterized by atypical, skin-homing T lymphocytes and have varying prognoses depending on subtype and disease stage. Numerous therapeutic options exist; however, many patients experience refractory disease and novel treatments are needed. RECENT FINDINGS: This review will highlight selected advances in CTCL treatment over the past year (2007-2008). Discoveries regarding the pathophysiology of mycosis fungoides and Sézary syndrome, the two most common CTCL types, have led to an expansion of new treatments and an increase in experience with multimodality therapy continues to increase. A number of reports have examined both combination regimens of currently available CTCL therapies as well as treatments approved for other dermatologic or oncologic conditions. Also, several novel skin-directed treatments and systemic compounds have been studied in all CTCL stages as well as in treatment-refractory disease. SUMMARY: There remains a continued impetus to develop and amass experience with new therapeutic options for CTCL, particularly for patients with advanced stage and treatment-refractory disease.
Asunto(s)
Linfoma Cutáneo de Células T/terapia , Neoplasias Cutáneas/terapia , Alquilantes/administración & dosificación , Anticarcinógenos/administración & dosificación , Terapia Combinada , Humanos , Factores Inmunológicos/administración & dosificación , Fototerapia , Piel/efectos de los fármacos , Trasplante de Células Madre , Resultado del TratamientoRESUMEN
The malignant cells in Sezary syndrome express the skin trafficking molecules' cutaneous lymphocyte associated antigen (CLA) and chemokine receptor 4 (CCR4). High levels of the CCR4 ligand, thymus, and activation-regulated chemokine (TARC), have been reported in the blood and skin of patients. The rexinoid X-receptor specific retinoid, bexarotene, has contributed to the resolution of cutaneous disease among patients. To evaluate the effects of bexarotene on skin trafficking molecule expression and chemotaxis, peripheral blood mononuclear cells from Sezary syndrome patients and healthy controls were treated with bexarotene in vitro. CCR4 and CLA expression levels and chemotaxis in response to TARC (6.25 ng/ml) were evaluated among lymphocytes before and after treatment with bexarotene (10 microM). Flow cytometric analysis was performed to evaluate CD4, CD26, CLA, and CCR4 cell surface expression. Transwell migration assays were performed to evaluate chemotaxis to TARC. Prior to treatment, malignant cells exhibited higher CCR4 expression (45-90%) and greater than four times more chemotaxis to TARC compared with healthy controls. After treatment with bexarotene for 36-96 hr, a 28% reduction in CCR4 expression was noted (P < 0.05) among the malignant population with an associated 9% decrease in chemotaxis to TARC (P < 0.05). Our results show that bexarotene may inhibit malignant cell trafficking to the skin through an ability to suppress CCR4 expression among Sezary syndrome lymphocytes.
Asunto(s)
Anticarcinógenos/farmacología , Quimiocinas CC/inmunología , Quimiotaxis de Leucocito/efectos de los fármacos , Receptores de Quimiocina/inmunología , Síndrome de Sézary/tratamiento farmacológico , Tetrahidronaftalenos/farmacología , Anciano , Bexaroteno , Estudios de Casos y Controles , Células Cultivadas , Quimiocina CCL17 , Quimiocinas CC/metabolismo , Evaluación Preclínica de Medicamentos , Femenino , Citometría de Flujo , Humanos , Leucocitos Mononucleares/efectos de los fármacos , Masculino , Persona de Mediana Edad , Receptores CCR4 , Receptores de Quimiocina/metabolismo , Síndrome de Sézary/inmunología , Síndrome de Sézary/metabolismo , Factores de TiempoRESUMEN
BACKGROUND: Multimodality biological response-modifier therapy that includes photopheresis, interferon, and bexarotene is the standard of care in our institution for advanced cutaneous T-cell lymphoma with peripheral blood involvement. We added psoralen plus long-wave UV-A (PUVA) to this regimen in 5 patients with Sézary syndrome. OBSERVATIONS: All patients responded with decreased Sézary counts, resolution of lymphadenopathy, and clearing of skin disease after the addition of PUVA. Adverse effects were well tolerated and managed via close clinical and laboratory follow-up. CONCLUSIONS: The addition of PUVA to a multimodality immunomodulatory regimen in patients with Sézary syndrome can result in rapid and sustained remission of both skin and blood-borne disease. Further in vitro and in vivo studies are needed.
Asunto(s)
Anticarcinógenos/uso terapéutico , Ficusina/uso terapéutico , Terapia PUVA , Fármacos Fotosensibilizantes/uso terapéutico , Síndrome de Sézary/tratamiento farmacológico , Neoplasias Cutáneas/tratamiento farmacológico , Tetrahidronaftalenos/uso terapéutico , Anciano , Anticarcinógenos/administración & dosificación , Bexaroteno , Quimioterapia Combinada , Femenino , Ficusina/administración & dosificación , Humanos , Masculino , Persona de Mediana Edad , Fármacos Fotosensibilizantes/administración & dosificación , Síndrome de Sézary/patología , Neoplasias Cutáneas/patología , Tetrahidronaftalenos/administración & dosificaciónRESUMEN
OBJECTIVE: To determine the efficacy of multimodality biologic response therapy for patients with cutaneous T-cell lymphoma (CTCL). DESIGN: Retrospective cohort study over a 14-year period. SETTING: Tertiary care university hospital. PATIENTS: A consecutive sample of patients was studied, all 47 of whom carried the clinical and laboratory diagnosis of CTCL: 68% of patients had stage III or IV disease, and 89% had circulating malignant T cells. INTERVENTIONS: All 47 patients received photopheresis for 6 or more cycles. Thirty-one patients received treatment with a combination of photopheresis and 1 or more systemic immunostimulatory agents, including interferon alfa, interferon gamma, sargramostim, or systemic retinoids for 3 or more months. MAIN OUTCOME MEASURES: Differences in pretreatment prognostic factors, response rates, and survival between patients receiving multimodality therapy and single-modality therapy or historical controls. RESULTS: A total of 79% of patients responded to therapy: 26% had complete remission, and 53% had a partial remission. Median survival from initiation of therapy was 74 months. Median survival for patients with stages III and IV and peripheral blood involvement was 55 months compared with 31 months for historical controls. Compared with the photopheresis monotherapy group, the patients receiving combination immunomodulatory therapy had a worse prognosis at the time of treatment initiation based on multiple prognostic factors. The positive response rates and median survival times were 84% and 74 months, respectively, compared with 75% and 66 months, respectively, for the combination immunomodulatory and photopheresis monotherapy groups (P =.47 for positive response rates and P =.51 for survival). CONCLUSIONS: Patients with advanced CTCL and multiple poor prognostic factors who receive treatment with combination immunomodulatory therapy experience higher clinical response rates and longer survival than historical controls. Although the group who received combination therapy had worse prognostic factors at baseline, they had better response rates and overall survival compared with those receiving photopheresis monotherapy.